Immunocore Holdings (IMCR) Income from Continuing Operations (2021 - 2026)
Immunocore Holdings (IMCR) posted Income from Continuing Operations of 12971000.0 for Q1 2026, up 143.15% sequentially from 30060000.0 in Q4 2025, and up 160.25% YoY from 4984000.0 in Q1 2025.
Powered by 
Analysis
Immunocore Holdings (IMCR) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Income from Continuing Operations for 6 years, with the latest figure at 12971000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 160.25% year-over-year to 12971000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27585000.0 (down 27.23% YoY) and the FY2025 annual result came in at 35514000.0, up 30.48% from the prior year.
- Income from Continuing Operations grew to 12971000.0 in Q1 2026 per IMCR's latest filing, from 30060000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 12971000.0 in Q1 2026 and troughed at 30060000.0 in Q4 2025.
- A 5-year average of 10741136.15 and a median of 14622719.55 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 864.24% in 2024, then plunged 102.24% in 2025.
- Over 5 years, Income from Continuing Operations stood at 29872138.48 in 2022, then jumped by 33.95% to 19730000.0 in 2023, then fell by 20.48% to 23771000.0 in 2024, then retreated by 26.46% to 30060000.0 in 2025, then jumped by 143.15% to 12971000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 12971000.0, 30060000.0, and 196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | -814,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -814,000.00 |
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -11.63 Mn |
| Mar 31, 2024 | -24.48 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -29.56 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -19.69 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |